Table 4 Reported concerns
| Long-term safety (%) | Adverse effects (%) | Lack of evidence (%) | Concerns in youth (%) | Dependence/tolerance (%) | Suicidality (%) | |
|---|---|---|---|---|---|---|
| Doxepin | 22.4 | 31.3 | 22.4 | 17.9 | 3.0 | 3.0 |
| Zaleplon | 16.4 | 20.9 | 22.4 | 35.8 | 29.9 | 0.0 |
| Tricyclics | 22.4 | 59.7 | 22.4 | 37.3 | 1.5 | 20.9 |
| Zolpidem | 16.4 | 20.9 | 20.9 | 34.3 | 32.8 | 0.0 |
| Lorazepam | 29.9 | 31.3 | 10.4 | 38.8 | 76.1 | 6.0 |